Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Abstract: An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment.
Abstract: The invention relates generally to the treatment of cancer. One embodiment of the invention provides a method of treating cancer in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Application
Filed:
August 22, 2014
Publication date:
July 14, 2016
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: The invention relates generally to the treatment of multiple myeloma. One embodiment of the invention provides a method of treating multiple myeloma (MM) in an individual, the method comprising: administering to the individual an effective amount of trichostatin A (TSA).
Type:
Application
Filed:
August 22, 2014
Publication date:
July 14, 2016
Inventors:
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Abstract: The invention relates to an aqueous paracetamol solution for its use by perfusion with a pH between 4.5 and 6.0, comprising at least one substance that can react with phenolates giving rise to its O-derivatives or other coordination compounds. The injectable paracetamol solution of the present invention has high stability, does not develop color over time and has a minimal content of impurities.
Abstract: The present invention is directed to the use of Trifluoroacetic acid and its physiologically acceptable salts as keratolytic agent to treat skin lesions characterized by the production of excessive skin by the epidermis.
Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
Type:
Application
Filed:
March 4, 2016
Publication date:
July 14, 2016
Applicant:
Infirst Healthcare Limited
Inventors:
Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
Abstract: Provided herein are compositions and methods to improve treatment of chronic infections, and reduce, delay, or inhibit formation of biofilms, using specific combinations of aminoglycoside antibiotics and treatment with one or more proton motive force (PMF) stimulating compounds. These novel methods are easily adapted to clinical settings as toxicity and efficacy of the antibiotics and metabolites used have already been studied in vivo, and as dosing for both the antibiotics and metabolites are known.
Type:
Application
Filed:
August 29, 2014
Publication date:
July 14, 2016
Applicants:
TRUSTEES OF BOSTON UNIVERSITY, THE GENERAL HOSPITAL CORPORATION
Inventors:
James J. Collins, Sylvain Meylan, Samuel Moskowitz
Abstract: A pharmacological composition for the treatment of bacterial and protozoal infections in a patient. The preferred pharmacological composition comprises a pharmaceutical carrier and an active composition selected from the group consisting of: a) an amount of sodium oxalate and an amount of oxalic acid, b) an amount of sodium citrate and an amount of citric acid, or c) mixtures of a) and b). The amounts and weight ratios of a) the sodium oxalate and oxalic acid, and b) the sodium citrate and citric acid in the active composition are such as to produce a safe and effective pharmacological composition. Sodium salts of other carboxylic acids may be used. The invention also relates to the method of using the pharmacological composition for the safe and effective treatment of bacterial infections, protozoal infections and dermatological diseases.
Abstract: The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C1-C6)alkyl or a CN; R1b represents H, an halogen or a (C1-C6)alkyl; R1c represents H or a (C1-C6)alkyl; R2 represents H, an halogen, an OH, an O—(C1-C6)alkyl or (C1-C6)alkyl; R3 represents H, an halogen, a (C1-C6)alkyl, an OH, an O—(C1-C6)alkyl, a CONH2 or CN; R4 represents H, an halogen or a (C1-C6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C1-C6)alkyl, or one of its enantiomers.
Type:
Application
Filed:
December 14, 2015
Publication date:
July 14, 2016
Inventors:
John FEUTRILL, Caroline LERICHE, David MIDDLEMISS
Abstract: The present invention relates to nutrition for infants and young children with particular lipid globules, resulting in programming the metabolism to an increased energy expenditure and improved mitochondrial functioning later in life when exposed to a high fat, high energy diet.
Type:
Application
Filed:
December 11, 2015
Publication date:
July 14, 2016
Applicant:
N.V. Nutricia
Inventors:
Annemarie OOSTING, Francina Dorothea KODDE, Marieke ABRAHAMSE-BERKEVELD, Eline Marleen VAN DER BEEK
Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
Abstract: The present disclosure provides methods for evaluating daily ammonia exposure based on a single fasting ammonia blood level measurement, as well as methods that utilize this technique to adjust the dosage of a nitrogen scavenging drug, determine whether to administer a nitrogen scavenging drug, and treat nitrogen retention disorders.
Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release matrices comprising fumarate esters are described.
Type:
Application
Filed:
March 18, 2016
Publication date:
July 14, 2016
Inventors:
Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
Abstract: Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising controlled release matrices comprising fumarate esters are described.
Type:
Application
Filed:
March 18, 2016
Publication date:
July 14, 2016
Inventors:
Tatyana Dyakonov, Sunil Agnihotri, Aqeel A. Fatmi
Abstract: This disclosure relates to nutritional formulas and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordinator difficulties. In certain embodiments, this disclosure relates to a nutritional formula comprising medium 5 chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.
Abstract: The invention relates to pharmaceutical compositions, as well as health functional food compositions and quasi-drug compositions, for preventing, treating, or improving rheumatoid arthritis, comprising a monoacetyldiacylglycerol compound as an active ingredient. The monoacetyldiacylglycerol of the invention is effective in inhibiting the phosphorylation of STAT-3 known to be a therapeutic target for rheumatoid arthritis. As the monoacetyldiacylglycerol is an effective therapeutic agent without toxicity, the monoacetyldiacylglycerol can overcome the side effects of the medicines currently used in the treatment of rheumatoid arthritis. Thus, the monoacetyldiacylglycerol can be used for preventing, treating or improving rheumatoid arthritis.
Type:
Application
Filed:
August 18, 2014
Publication date:
July 14, 2016
Inventors:
Jae Wha KIM, Sei Ryang OH, Kyung Seop AHN, Ho Bum KANG, Beom Su PARK, Tae Suk LEE, Jong Koo KANG, Young Sik JUNG, Yong-Hae HAN, Ki-Young SOHN
Abstract: The present invention relates to a pharmaceutical composition containing a monoacetyldiacylglycerol compound as an active ingredient for preventing or treating asthma, and a functional health food composition for preventing or treating asthma. The monoacetyldiacylglycerol compound of the present invention inhibits the expression of IL-4 in EL-4 cells, which are mouse T cell lymphoma cells, reduces hypersensitivity of airway in an asthma-induced animal model, and inhibits the infiltration of inflammatory cells into the bronchial tube. In addition, the compounds of the present invention inhibit the generation of IgE in the serum and bronchoalveolar lavage fluid, have an excellent effect of inhibiting the expression of Th2 cytokines (IL-4, IL-5, and IL-13) in the lung, thereby overcome side effects of the currently used therapeutic agents for asthma, have no toxicity, and exhibit a superior therapeutic effect, and thus can be useful as a composition for preventing, treating, and alleviating asthma.
Type:
Application
Filed:
August 19, 2014
Publication date:
July 14, 2016
Applicant:
KOREA RESEARCH INSTITUTE OF BIO SCIENCE AND BIOTECHNOLOGY
Inventors:
Sei-Ryang OH, Kyung Seop AHN, Su Ui LEE, In Sik SHIN, Na-Rae SHIN, Tae-Suk LEE, JongKoo KANG, Young-Sik JUNG, Yong-Hae HAN, Ki Young SOHN
Abstract: A 12-hour anti-tussive modified release solid tablet or capsule is described which comprises a benzonatate adsorbate in a matrix with a sufficient amount of one or more pharmaceutically acceptable modified release pH-independent, substances to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 25% release of the benzonatate within 1 hour as determined in an in vitro dissolution assay.
Type:
Application
Filed:
March 21, 2016
Publication date:
July 14, 2016
Inventors:
Andrea Nelson, Quin-Zene Chen, Harsh Mehta, Yu-Hsing Tu
Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
Type:
Application
Filed:
March 18, 2016
Publication date:
July 14, 2016
Inventors:
Gee-Hong Kuo, Rui Zhang, Aihua Wang, Alan R. DeAngelis
Abstract: The present invention relates to the treatment of wounds.
Type:
Application
Filed:
August 25, 2014
Publication date:
July 14, 2016
Applicant:
Nitto Denko Corporation
Inventors:
Geofrey De Visscher, Walter Eevers, Nicolas Schüwer, Takayuki Shigematsu, Mayu Takeiri, Jeffrey A. Hubbell, Federico Tortelli, De Titta Alexandre, Sandra Amiguet Vercher
Abstract: Methods for making trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol are disclosed herein. In one embodiment, a trans-(?)-?9-tetrahydrocannabinol composition is prepared by allowing a composition comprising (±)-?9-tetrahydrocannabinol to separate on a chiral stationary phase to provide a trans-(?)-?9-tetrahydrocannabinol composition comprising at least about 99% by weight of trans-(?)-?9-tetrahydrocannabinol based on the total amount of trans-(?)-?9-tetrahydrocannabinol and trans-(+)-?9-tetrahydrocannabinol. The invention also relates to methods for treating or preventing a condition such as pain comprising administering to a patient in need thereof an effective amount of a trans-(?)-?9-tetrahydrocannabinol having a purity of at least about 98% based on the total weight of cannabinoids.
Type:
Application
Filed:
March 4, 2016
Publication date:
July 14, 2016
Inventors:
Arie L. GUTMAN, Marina ETINGER, Irina FEDOTEV, Ram KHANOLKAR, Gennady NISNEVICH, Boris PERTSIKOV, Igor RUKHMAN, Boris TISHIN
Abstract: The invention provides compositions comprising wilforlide A for overcoming drug resistance in cancer therapy, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods and compositions for treating a cancer are disclosed. The method administers to a patient in need thereof a combination of wilforlide A and a chemotherapeutic drug. Wilforlide A and chemotherapeutic drug are administered in a combined amount effective to treat the can cer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug alone.
Type:
Application
Filed:
September 12, 2014
Publication date:
July 14, 2016
Inventors:
Moses Sing Sum CHOW, Ying HUANG, Jinghua Jeffrey WANG, Ranadheer RAVULA, Zhi Jun WANG
Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
Type:
Application
Filed:
December 10, 2015
Publication date:
July 14, 2016
Inventors:
MARK D. BEDNARSKI, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
Abstract: The present invention relates to methods of inhibiting native and promiscuous uptake of biogenic amine neurotransmitters with triple reuptake inhibitors in the treatment of conditions affected by monoamine neurotransmitters.
Abstract: The present invention relates to compounds of formula (I): wherein R1 and R2 are as defined herein. In certain embodiments, the compounds of the present invention are inhibitors of ROR?t and are useful in the treatment of diseases and conditions mediated by ROR?t.
Abstract: The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient, which is selected from (1r,4r)-6?-fluoro-N,N-dimethyl-4-phenyl-4?,9?-dihydro-3?H-spiro[cyclohexane-1,1?-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient, which is a propionic acid derivative selected from the group consisting of ibuprofen, naproxen, ketoprofen, flurbiprofen, fenoprofen, fenbufen, suprofen, pirprofen, indoprofen, tiaprofenic acid, oxaprozin, ibuproxam, flunoxaprofen, alminoprofen, naproxcinod, and the physiologically acceptable salts thereof.
Type:
Application
Filed:
March 21, 2016
Publication date:
July 14, 2016
Inventors:
Stefanie FROSCH, Klaus LINZ, Klaus SCHIENE
Abstract: The invention relates to a combination which comprises: (a) a HDAC inhibitor; and (b) an anti-thrombocytopenia drug, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of a proliferative diseases.
Type:
Application
Filed:
November 30, 2015
Publication date:
July 14, 2016
Inventors:
Peter Wisdom Atadja, Ricky Wayne Johnstone, Henry Miles Prince, Mark John Bishton, Simon James Harrison
Abstract: Compositions and methods for inhibiting fungal growth by administering AR-12 to a host infected with a fungus such as Histoplasma capsulatum, Aspergillus fumigatus, and Trichophyton rubrum, Paecilomyces, Rhizopus, Fusarium, Scedosporium, Lomentospora, Apophysomyces, Coccidioides, Blastomyces, non-albicans Candida, and Pneumocytis are provided.
Type:
Application
Filed:
January 7, 2016
Publication date:
July 14, 2016
Inventors:
Chad A. Rappleye, Alexander Zukiwski, Stefan Proniuk
Abstract: The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect provides pharmaceutical compositions comprising at least one pyrazoloanthrone or functional a derivative or a functional analogue thereof, and optionally with one or more additional agents such as chemotherapeutic agents.
Abstract: Disclosed are novel pharmaceutical compositions containing 3?-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinol-2?-hydroxy-[1,1?-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.
Abstract: Methods for antihypertensive drug dosing by pharmacokinetic parameter determination. In one embodiment, the antihypertensive drug is olmesartan and the pharmacokinetic parameter is AUC. The methods are effective for treating hypertension.
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Type:
Application
Filed:
March 11, 2016
Publication date:
July 14, 2016
Inventors:
PIYASENA HEWAWASAM, JOHN F. KADOW, OMAR D. LOPEZ, NICHOLAS A. MEANWELL, YONG TU, ALAN XIANGDONG WANG, NINGNING XU, SAMAYAMUNTHULA VENKATA SATYA ARUN KUMAR GUPTA, POTHUKANURI SRINIVASU, INDASI GOPI KUMAR, PONUGUPATI SURESH KUMAR, MAKONEN BELEMA, ROBERT A. FRIDELL, MIN GAO, JULIE A. LEMM, DONALD R. O'BOYLE, II, JIN-HUA SUN, CHUNFU WANG, YING-KAI WANG
Abstract: The invention relates generally to muscarinic agonists, which are useful for stimulating muscarine receptors, and treating cognitive disorders. Included among the muscarinic agonists disclosed herein are oxadiazole derivatives, compositions, and preparations thereof. Methods of synthesizing oxadiazole compounds also are provided. This disclosure also relates in part to compositions for enhancing cognitive function in subjects such as humans, the compositions comprising a muscarinic agonist or a pharmaceutically suitable form thereof. This disclosure relates in part to methods of treating animals such as humans by administering such compositions.
Type:
Application
Filed:
November 2, 2015
Publication date:
July 14, 2016
Inventors:
Brent D. Abraham, Richard R. Copp, James G. Farnham, Seth A. Hanson, Michael L. Hendrickson, Jeffrey C. Ockuly, Trevor M. Twose, Melinda L. Verdone
Abstract: The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.
Type:
Application
Filed:
February 16, 2016
Publication date:
July 14, 2016
Inventors:
Neil ALMSTEAD, Guangming CHEN, Samit HIRAWAT, Peter Seongwoo HWANG, Gary M. KARP, Paul KENNEDY, Langdon MILLER, Young-Choon MOON, Hongyu REN, James J. TAKASUGI, Ellen M. WELCH, Richard G. WILDE
Abstract: A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition.
Abstract: An antiemetic system for weekly application that contains two identical transdermal patches, a first patch and a second patch, the first patch to be administered to a subject for 3 days followed by administering the second patch to the subject for 4 days. Also disclosed is a method of treating an emesis in a subject with the above-described antiemetic system.
Abstract: A method of inducing an anti-retroviral immune response by counter-acting retro-virus induced anti-apoptosis is disclosed. The present invention relates, at least in part, to agents and methods for treating, inhibiting, vaccinating or controlling HIV. In certain non-limiting aspects, it relates to the reduction of viral load in an HIV-1 infected subject, while simultaneously developing immunological responsiveness within the subject toward HIV-1 that continues after the agent is removed or excreted from the subject's body.
Type:
Application
Filed:
August 19, 2014
Publication date:
July 14, 2016
Inventors:
Hartmut M. Hanauske-Abel, Paul Palumbo, Bernadette M. Cracchiolo, Axel R. Hanauske, Michael B. Mathews
Abstract: The present invention provides uses of a salt adduct comprising at least one positively charged moiety being a pyridoxine or a derivative thereof and at least one carboxylated 5- to 7-membered lactam ring, optionally additionally substituted, for the preparation of a medicament for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition in a subject. Additionally, the invention provides use of said salt adducts for the preparation of medicaments for the improvement of cognitive functions in a healthy subject.
Abstract: Provided are methods of treating and/or preventing dermatological disorders. Provided are methods of reducing skin inflammation, reducing pain, and/or reducing itch in a subject in need thereof. The methods may include administering to the subject an effective amount of a TRPA1 and/or TRPV4 inhibitor. Further provided are compositions including a TRPA1 and/or TRPV4 inhibitor compound in combination with a carrier, vehicle, or diluent that is suitable for topical application.
Abstract: A composition, a method for administering an anti-seizure composition, and a method for treating a seizure are described. In an implementation, a composition comprises a peroxisome proliferator activated receptor gamma (PPAR?) antagonist that is administered to an individual, where the individual has been administered a ketogenic diet. In an implementation, a method for administering an anti-seizure composition comprises administering a ketogenic diet to an individual; and concurrently administering a therapeutically effective dose of a peroxisome proliferator activated receptor gamma (PPAR?) antagonist to the individual In an implementation, a method for treating a seizure comprises administering a therapeutically effective dose of a peroxisome proliferator activated receptor gamma (PPAR?) antagonist to an individual on a ketogenic diet and suffering from seizures.
Type:
Application
Filed:
January 13, 2016
Publication date:
July 14, 2016
Inventors:
Timothy A. Simeone, Kristina A. Simeone
Abstract: The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and inhibitors of Heat Shock Protein 90, and the uses of such combinations in the treatment of proliferative diseases, more specifically PI3K dependent diseases, more specifically PI3K-alpha dependent diseases.
Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
Abstract: Provided is a composition for preventing or treating stroke, and more particularly, a pharmaceutical composition for preventing or treating stroke, which contains a peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (Pin1) inhibitor as an active ingredient. The Pin1 inhibitor has a neuroprotective effect in which production of NICD1, which is a Notch1 signaling activation product activated in ischemic stroke, is regulated, and cerebral infarction and deficits of neuronal cells triggered by ischemic stroke and neuronal cell death are reduced, and thus can be useful in preventing or treating stroke and also useful in treating a cerebrovascular disease and stroke-associated dementia.
Type:
Application
Filed:
August 17, 2015
Publication date:
July 14, 2016
Applicant:
RESEARCH & BUSINESS FOUNDATION SUNGKYUNKWAN UNIVERSITY
Abstract: Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharmaceutical ingredient are described.
Type:
Application
Filed:
October 7, 2015
Publication date:
July 14, 2016
Inventors:
Saujanya Gosangari, Justin Hughey, Tatyana Dyakonov, George VAMVAKAS, Aqeel A. FATMI
Abstract: The present disclosure relates to an oral, immediate release, abuse deterrent pill containing at least one active pharmaceutical ingredient susceptible to abuse which is homogenously spread throughout a carrier matrix used to deter abuse. The pill is prepared using hot melt extrusion and a forming unit through a continuous process. The formed pill is abuse deterrent to parenteral administration due at least to particle size, viscosity, or purity limitations.
Type:
Application
Filed:
August 12, 2014
Publication date:
July 14, 2016
Applicants:
Pharmaceutical Manufacturing Research Services, Inc., Pharmaceutical Manufacturing Research Services, Inc.
Inventors:
Edwin R. Thompson, Eric R. Thompson, Nicholas R. Myslinski, Steven F. Kemeny
Abstract: Disclosed are pyruvate kinase M2 activators, which are, bis sulfonamide piperazinyl compounds of Formula (I) and 2,4-disubstituted 4H-thieno[3,2-b]pyrrole-2-(substituted benzyl)pyridazin-3(2H)ones of Formula (II), wherein L and R1 to R16 are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer and anemia,
Type:
Application
Filed:
March 21, 2016
Publication date:
July 14, 2016
Applicant:
The United States of America, as represented by the Secretary, Department of Health and Human Serv
Inventors:
Craig J. Thomas, Douglas S. Auld, James Inglese, Amanda P. Skoumbourdis, Jian-Kang Jiang, Matthew B. Boxer